Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
Clinical trial NCT07077616 · RECRUITING
Trial details
- NCT number
- NCT07077616
- Sponsor
- Biogenea Pharmaceuticals Ltd.
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2027-12-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.